HLA-B27 associated spondyloarthropathy, vasculitis, and amyloid enteropathy: Response to infliximab

Journal of Rheumatology

Volumn 32, Issue 2, 2005, Pages 382-385

  Stamp, Lisa K ^a   O'Donnell, John L ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NONE

Author keywords

Amyloidosis; Aortitis; HLA B27 spondyloarthropathy; Infliximab

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; PREDNISONE;

ADULT; AORTITIS; ARTERY OCCLUSION; ARTICLE; AXILLARY ARTERY; BIOPSY; CASE REPORT; DIARRHEA; ENTEROPATHY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; IRON DEFICIENCY ANEMIA; LABORATORY TEST; PRIORITY JOURNAL; SPONDYLOARTHROPATHY; SUBCLAVIAN ARTERY; VASCULITIS;

ADULT; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AORTITIS; DRUG THERAPY, COMBINATION; FEMALE; GASTROENTERITIS; HLA-B27 ANTIGEN; HUMANS; METHOTREXATE; PREDNISONE; SPONDYLARTHROPATHIES; TREATMENT OUTCOME;

EID: 13444257373     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Stamp L, Lambie N, O'Donnell J. HLA-B27 associated spondyloarthropathy and severe ascending aortitis. J Rheumatol 2000;27:2038-40.
2. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-α, IL-1β, and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
3. Braun J, Bollow M, Neure L, et al. Use of immunohistological and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
4. Redlich K, Gortz B, Hayer S, et al. Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum 2004;50:1001-05.
5. De Keyser F, Baeten D, van den Bosch F, Kruithof E, Mielants H, Veys E. Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation. Rheum Dis Clin N Am 2003;29:463-79.
6. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
7. Van den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
8. Baeten D, Kruithof E, van den Bosch F, et al. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondyloarthropathy. Arthritis Rheum 2001;44:186-95.
9. Kruithof E, Baeten D, van den Bosch F, Mielants H, Veys E, De Keyser F. Modulation of vascularity and expression of adhesion molecules by TNF-alpha blockade in spondyloarthropathy: Histological and serologic evaluation in a placebo-controlled trial [abstract]. Arthritis Rheum 2002;46 Suppl:S430.
10. Lange U, Boss B, Teichmann J, Klor H, Neeck G. Serum amyloid A: an indicator of inflammation in ankylosing spondylitis. Rheumatol Int 2000;19:119-22.
11. Niewold T, Gruys E, Arakawa T, Shirahama T, Kisilevsky R. Recombinant human tumor necrosis factor-α (rhTNF-α) and rhTNF-α analogue enhance amyloid deposition in the Syrian hamster. Scand J Immunol 1993;37:29-32.
12. Gillmore J, Lovat L, Persey M, Pepys M, Hawkins P. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.
13. Charles P, Elliott M, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
14. Elkayam O, Hawkins P, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3.
15. Drewe E, McDermott E, Powell R. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 2000;343:1044-5.
16. Gottenberg J, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 2003;48:2019-24.